Circulating Cell-free Cancer-testis MAGE-A RNA, BORIS RNA, Let-7b and MiR-202 in the Blood of Patients with Breast Cancer and Benign Breast Diseases

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Jul 2

PMID 24983365

Citations 46

Authors

S A Joosse

V Muller

B Steinbach

K Pantel

H Schwarzenbach

Affiliations

Soon will be listed here.

Abstract

Background: MAGE-A (melanoma-associated antigen-A) are promising targets for specific immunotherapy and their expression may be induced by the epigenetic factor BORIS.

Methods: To determine their relevance for breast cancer, we quantified the levels of MAGE-A1, -A2, -A3, -A12 and BORIS mRNA, as well as microRNAs let-7b and miR-202 in pre- and postoperative serum of 102 and 34 breast cancer patients, respectively, and in serum of 26 patients with benign breast diseases and 37 healthy women by real-time PCR. The mean follow-up time of the cancer patients was 6.2 years.

Results: The serum levels of MAGE-A and BORIS mRNA, as well as let-7b were significantly higher in patients with invasive carcinomas than in patients with benign breast diseases or healthy women (P<0.001), whereas the levels of miR-202 were elevated in both patient cohorts (P<0.001). In uni- and multivariate analyses, high levels of miR-202 significantly correlated with poor overall survival (P=0.0001). Transfection of breast cancer cells with synthetic microRNAs and their inhibitors showed that let-7b and miR-202 did not affect the protein expression of MAGE-A1.

Conclusions: Based on their cancer-specific increase in breast cancer patients, circulating MAGE-A and BORIS mRNAs may be further explored for early detection of breast cancer and monitoring of MAGE-directed immunotherapies. Moreover, serum miR-202 is associated with prognosis.

Citing Articles

HetFCM: functional co-module discovery by heterogeneous network co-clustering.

Tan H, Guo M, Chen J, Wang J, Yu G Nucleic Acids Res. 2023; 52(3):e16.

PMID: 38088228 PMC: 10853805. DOI: 10.1093/nar/gkad1174.

An Epidemiological Systematic Review with Meta-Analysis on Biomarker Role of Circulating MicroRNAs in Breast Cancer Incidence.

Padroni L, De Marco L, Dansero L, Fiano V, Milani L, Vasapolli P Int J Mol Sci. 2023; 24(4).

PMID: 36835336 PMC: 9967215. DOI: 10.3390/ijms24043910.

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer.

Rzhevskiy A, Kapitannikova A, Butnaru D, Shpot E, Joosse S, Zvyagin A Biomedicines. 2022; 10(12).

PMID: 36551871 PMC: 9776104. DOI: 10.3390/biomedicines10123115.

Molecular Management of High-Grade Serous Ovarian Carcinoma.

Punzon-Jimenez P, Lago V, Domingo S, Simon C, Mas A Int J Mol Sci. 2022; 23(22).

PMID: 36430255 PMC: 9692799. DOI: 10.3390/ijms232213777.

A regulatory network comprising let-7 miRNA and SMUG1 is associated with good prognosis in ER+ breast tumours.

Lirussi L, Ayyildiz D, Liu Y, Montaldo N, Carracedo S, Aure M Nucleic Acids Res. 2022; 50(18):10449-10468.

PMID: 36156150 PMC: 9561369. DOI: 10.1093/nar/gkac807.

References

Tang Z, Ow G, Thiery J, Ivshina A, Kuznetsov V . Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer. 2013; 134(2):306-18. DOI: 10.1002/ijc.28371. View

Sang M, Lian Y, Zhou X, Shan B . MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011; 29(47):8496-500. DOI: 10.1016/j.vaccine.2011.09.014. View

Riethdorf S, Pantel K . Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology. 2008; 75(2):140-8. DOI: 10.1159/000123852. View

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100(2):229-35. DOI: 10.1007/s10549-006-9242-8. View

Kim V . MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6(5):376-85. DOI: 10.1038/nrm1644. View

Martin-Kleiner I . BORIS in human cancers -- a review. Eur J Cancer. 2011; 48(6):929-35. DOI: 10.1016/j.ejca.2011.09.009. View

Krol J, Loedige I, Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010; 11(9):597-610. DOI: 10.1038/nrg2843. View

Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z . Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One. 2012; 7(9):e44399. PMC: 3435307. DOI: 10.1371/journal.pone.0044399. View

10.

Jungbluth A, Busam K, Kolb D, Iversen K, Coplan K, Chen Y . Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer. 2000; 85(4):460-5. View

11.

Meek D, Marcar L . MAGE-A antigens as targets in tumour therapy. Cancer Lett. 2012; 324(2):126-32. DOI: 10.1016/j.canlet.2012.05.011. View

12.

Nguyen P, Bar-Sela G, Sun L, Bisht K, Cui H, Kohn E . BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol Cell Biol. 2008; 28(21):6720-9. PMC: 2573239. DOI: 10.1128/MCB.00568-08. View

13.

Kwon S, Kang S, Ro J, Jeon C, Park J, Lee E . The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma. Cancer. 2005; 104(2):251-6. DOI: 10.1002/cncr.21162. View

14.

Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Schlimok G . Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst. 1995; 87(15):1162-8. DOI: 10.1093/jnci/87.15.1162. View

15.

Cookson V, Bentley M, Hogan B, Horgan K, Hayward B, Hazelwood L . Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr). 2012; 35(4):301-8. DOI: 10.1007/s13402-012-0089-1. View

16.

Caballero O, Chen Y . Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009; 100(11):2014-21. PMC: 11158245. DOI: 10.1111/j.1349-7006.2009.01303.x. View

17.

Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker R . Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2010; 127(1):69-80. DOI: 10.1007/s10549-010-0972-2. View

18.

Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger K . Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile. J Proteome Res. 2009; 8(4):2004-14. DOI: 10.1021/pr8009758. View

19.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C . let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131(6):1109-23. DOI: 10.1016/j.cell.2007.10.054. View

20.

Hong J, Kang Y, Abdullaev Z, Flanagan P, Pack S, Fischette M . Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 2005; 65(17):7763-74. DOI: 10.1158/0008-5472.CAN-05-0823. View